Correlation between percent GATA2+ bone marrow cells and clinicopathologic metrics in adult MDS cases
| Variable . | P value, test used . |
|---|---|
| Diagnosis | < .001, J |
| RS/SLD/MLD/U | |
| EB-1 | |
| EB-2 | |
| Age at diagnosis, y | .863, S |
| Sex | .552, W |
| Therapy related | .317, W |
| Marrow cellularity | .960, S |
| Marrow dysplasia∗ | |
| Erythroid | .509, W |
| Myeloid | .038, W |
| Megakaryocyte | .971, W |
| Blood dysplasia | |
| Erythroid | .857, W |
| Myeloid | .675, W |
| Megakaryocyte | .834, W |
| Cytopenia | |
| RBCs | Insufficient Data |
| Neutrophils | .576, W |
| Platelets | .119, W |
| Ring sideroblasts† | .270, J |
| Blasts (%) | < .001, S |
| Abnormal cytogenetics | .378, W |
| Complex cytogenetics | .048, W |
| Number of P/LP mutations | .579, J |
| 0-1 | |
| 2-3 | |
| 4-6 |
| Variable . | P value, test used . |
|---|---|
| Diagnosis | < .001, J |
| RS/SLD/MLD/U | |
| EB-1 | |
| EB-2 | |
| Age at diagnosis, y | .863, S |
| Sex | .552, W |
| Therapy related | .317, W |
| Marrow cellularity | .960, S |
| Marrow dysplasia∗ | |
| Erythroid | .509, W |
| Myeloid | .038, W |
| Megakaryocyte | .971, W |
| Blood dysplasia | |
| Erythroid | .857, W |
| Myeloid | .675, W |
| Megakaryocyte | .834, W |
| Cytopenia | |
| RBCs | Insufficient Data |
| Neutrophils | .576, W |
| Platelets | .119, W |
| Ring sideroblasts† | .270, J |
| Blasts (%) | < .001, S |
| Abnormal cytogenetics | .378, W |
| Complex cytogenetics | .048, W |
| Number of P/LP mutations | .579, J |
| 0-1 | |
| 2-3 | |
| 4-6 |
Significance indicated in bold. EB, excess blasts; MLD, multilineage dysplasia; P/LP, pathogenic/likely pathogenic; RBCs, red blood cells; RS, ring sideroblasts; SLD, single lineage dysplasia; U, unclassifiable.
Statistical tests: J, Jonckheere; W, Wilcoxon rank-sum; S, Spearman correlation; K, Kruskal-Walls.
n = 46.
n = 42.